The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study. The New Drug Application (NDA) for SPN-830 ...

Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been marked by ...

Credit: Thinkstock. SPN-830 provides a continuous subcutaneous infusion of apomorphine through an infusion pump. The Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act ...

Levodopa is the gold standard for Parkinson's disease treatment, but not all patients find success with commonly prescribed tablets and pills. For those with limited motor control, a more sustainable ...

If a patient with Parkinson’s disease fits into the “5-2-1” screening criteria– five times of oral tablet, stiffness for two hours and one hour of uncontrollable movements despite medication– laid ...

After successfully launching the D-mine Pump, a micro infusion device designed to provide precise continuous subcutaneous drug delivery for PD patients, the product family has been extended to include ...

ROCKVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of ...

Learn everything you need to know about Apomorphine-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings ...

Onapgo is approved for adult Parkinson’s patients experiencing motor fluctuations. Credit: Inside Creative House via Getty Images. · Pharmaceutical Technology · Inside Creative House via Getty Images.